高乌甲素贴片用于术后疼痛的预算影响分析OA

Objective To predict the possible impact on the medical insurance fund in the next three years after lappaconitine patch was included in the medical insurance drug list as the indication of postoperative pain,and to provide a reference for the medical insurance department.Methods According to the guidelines for Pharmacoeconomic evaluation in China,a budget impact analysis model was constructed.The research period was from 2024 to 2026,and the impacts of lappaconitine patches on the expenditure of medical insurance fund under the two scenarios of inclusion and non-inclusion of medical insurance payment were compared.Results After lappaconitine patch was included in the medical insurance drug list,The expenditure of medical insurance fund will increase by 127.844,396 million yuan and 55.054,218 million yuan from 2024 to 2025,but the expenditure of medical insurance fund will decrease by 33.908,095 million yuan in 2026.Conclusion After the lappaconitine patch is included in the reimbursement of medical insurance,the impact on the expenditure of medical insurance fund is small.